Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris

NCT00424801 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2009-05-06

No results posted yet for this study

Summary

The purpose of this study is to determine if long-term vasodilatory treatment is more effective than the standard treatment in hypertensive patients with microvascular angina pectoris

Conditions

Interventions

DRUG

Lercanidipine

Individual titration, max. dose 20 mg OD for 8 months

DRUG

Valsartan

Individual titration, max. dose 160 mg OD for 8 months

DRUG

Nicorandil

Individual titration, max. dose 20 mg BD for 8 months

DRUG

Doxazosin

Individual titration, max. dose 4 mg OD for 8 months

DRUG

Moxonidin

Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 0,2 mg OD for 8 months

DRUG

Pindolol

Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 10 mg OD for 8 months

DRUG

Amiloride, hydrochlorothiazide

Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 1 tbl. OD for 8 months

Sponsors & Collaborators

  • Danish Cardiovascular Research Academy

    collaborator UNKNOWN
  • Danish Heart Foundation

    collaborator OTHER
  • Novartis

    collaborator INDUSTRY
  • University of Aarhus

    lead OTHER

Principal Investigators

  • Michael N Præstholm, MD · University of Aarhus

  • Kent L Christensen, MD, DrMSc · Aarhus Hospital, medical-cardiologic dept. A

  • Won Yong Kim, MD, DrMSc · Skejby Hospital, cardiologic dept. B

  • Hans Erik Bøtker, MD, DrMSc · Skejby Hospital, cardiologic dept. B

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00424801 on ClinicalTrials.gov